Read by QxMD icon Read


Carlo Dall'Oca, Stefano Breda, Nicholas Elena, Roberto Valentini, Elena Manuela Samaila, Bruno Magnan
BACKGROUND AND AIM OF THE WORK: Osteoarthritis will become even more common in the near future since the average life span is steadily growing. Pain and loss of function are the main complaints reported by patients, inevitably leading towards a worsened daily life performance. New modern techniques have been developed with advanced cell based therapies. Mesenchymal stem cells (MSC) have the inner ability to mature into different types of cells depending on the stimuli they undergo. This technique has already been proven successful in the knee and, with this retrospective study, we would like to assess its feasibility in the hip joint...
January 10, 2019: Acta Bio-medica: Atenei Parmensis
Jay Panchal, Gerard Malanga, Mitchell Sheinkop
The aim of this study was to evaluate the safety and efficacy of using autologous, micro-fractured, minimally manipulated adipose tissue in patients with refractory knee osteoarthritis (OA). A total of 17 subjects (26 knees) with a median age of 72 years (range: 54-78 years) and a history of knee OA (Kellgren-Lawrence, grade of 3 or 4) underwent treatment with ultrasound-guided injection of micro-fractured adipose tissue. Micro-fractured fat was obtained using a minimal manipulation technique in a closed system (Lipogems), without the addition of enzymes or any other additives...
November 2018: American Journal of Orthopedics
Bianca Vezzani, Isaac Shaw, Hanna Lesme, Li Yong, Nusrat Khan, Carlo Tremolada, Bruno Péault
Autologous adipose tissue is used for tissue repletion and/or regeneration as an intact lipoaspirate or as enzymatically derived stromal vascular fraction (SVF), which may be first cultured into mesenchymal stem cells (MSCs). Alternatively, transplant of autologous adipose tissue mechanically fragmented into submillimeter clusters has recently showed remarkable efficacy in diverse therapeutic indications. To document the biologic basis of the regenerative potential of microfragmented adipose tissue, we first analyzed the distribution of perivascular presumptive MSCs in adipose tissue processed with the Lipogems technology, observing a significant enrichment in pericytes, at the expense of adventitial cells, as compared to isogenic enzymatically processed lipoaspirates...
December 2018: Stem Cells Translational Medicine
M Garcia-Contreras, F Messaggio, A J Mendez, C Ricordi
OBJECTIVE: In this study, we evaluated the metabolomic profiling of cryopreserved Lipogems® tissue products and the initial lipoaspirates before microfracturing, to determine altered metabolites that could result from the non-enzymatic processing or the cryopreservation method. MATERIALS AND METHODS: Human Lipoaspirate samples (n=10) were divided in two aliquots, of which one was non-processed and the other was processed by Lipogems® device. Non-processed lipoaspirates and Lipogems® processed tissues were stored at -80°C fresh frozen (N=3 per group) or in the presence of 0...
May 2018: European Review for Medical and Pharmacological Sciences
Valentina Coccè, Anna Brini, Aldo Bruno Giannì, Valeria Sordi, Angiola Berenzi, Giulio Alessandri, Carlo Tremolada, Silvia Versari, Antonio Bosetto, Augusto Pessina
The adipose tissue is a good source of mesenchymal stromal cells that requires minimally invasive isolation procedures. To ensure reproducibility, efficacy, and safety for clinical uses, these procedures have to be in compliant with good manufacturing practices. Techniques for harvesting and processing human adipose tissue have rapidly evolved in the last years, and Lipogems® represents an innovative approach to obtain microfragmented adipose tissue in a short time, without expansion and/or enzymatic treatment...
2018: Stem Cells International
G A Casarotti, P Chiodera, C Tremolada
OBJECTIVE: Urogenital atrophy is a degenerative process that may occur during menopause causing debilitating disorders and painful symptomatology. Estrogen therapy slows the onset of atrophy, but it requires ongoing therapy to maintain its effectiveness. To mitigate the degenerative evolutions associated with menopause, patients may benefit from new therapeutic approaches, such as the use of mesenchymal stem cells. Among the many sources, the adipose tissue is considered one of the smartest, due to its abundance and easy access...
January 2018: European Review for Medical and Pharmacological Sciences
Carlo Tremolada, Valeria Colombo, Carlo Ventura
In the past few years, interest in adipose tissue as an ideal source of mesenchymal stem cells (MSCs) has increased. These cells are multipotent and may differentiate in vitro into several cellular lineages, such as adipocytes, chondrocytes, osteoblasts, and myoblasts. In addition, they secrete many bioactive molecules and thus are considered "mini-drugstores." MSCs are being used increasingly for many clinical applications, such as orthopedic, plastic, and reconstructive surgery. Adipose-derived MSCs are routinely obtained enzymatically from fat lipoaspirate as SVF and/or may undergo prolonged ex vivo expansion, with significant senescence and a decrease in multipotency, leading to unsatisfactory clinical results...
2016: Current Stem Cell Reports
Valentina Ceserani, Anna Ferri, Angiola Berenzi, Anna Benetti, Emilio Ciusani, Luisa Pascucci, Cinzia Bazzucchi, Valentina Coccè, Arianna Bonomi, Augusto Pessina, Erica Ghezzi, Offer Zeira, Piero Ceccarelli, Silvia Versari, Carlo Tremolada, Giulio Alessandri
BACKGROUND: Adipose-derived mesenchymal stromal cells (Ad-MSCs) are a promising tool for advanced cell-based therapies. They are routinely obtained enzymatically from fat lipoaspirate (LP) as SVF, and may undergo prolonged ex vivo expansion, with significant senescence and decline in multipotency. Besides, these techniques have complex regulatory issues, thus incurring in the compelling requirements of GMP guidelines. Hence, availability of a minimally manipulated, autologous adipose tissue would have remarkable biomedical and clinical relevance...
2016: Vascular Cell
Carlo Tremolada, Camillo Ricordi, Arnold I Caplan, Carlo Ventura
The idea that basic science should be the starting point for modern clinical approaches has been consolidated over the years, and emerged as the cornerstone of Molecular Medicine. Nevertheless, there is increasing concern over the low efficiency and inherent costs related to the translation of achievements from the bench to the bedside. These burdens are also perceived with respect to the effectiveness of translating basic discoveries in stem cell biology to the newly developing field of advanced cell therapy or Regenerative Medicine...
2016: Methods in Molecular Biology
Giovanni Marfia, Stefania Elena Navone, Loubna Abdel Hadi, Moira Paroni, Valeria Berno, Matteo Beretta, Roberta Gualtierotti, Francesca Ingegnoli, Vincenzo Levi, Monica Miozzo, Jens Geginat, Lorenzo Fassina, Paolo Rampini, Carlo Tremolada, Laura Riboni, Rolando Campanella
Central nervous system (CNS) inflammation is primarily driven by microglial cells which secrete proinflammatory cytokines and undergo proliferation upon activation, as it occurs in neurodegenerative diseases. Uncontrolled or prolonged CNS inflammation is potentially harmful and can result in cellular damage. Recently, many studies have focused on human adipose tissue as an attractive source of cytokines with immunosuppressive properties that potentially modulate inflammation. Our study aimed to evaluate if different methods of human tissue collection could affect adipose mesenchymal stem cell (ADSC)-derived cytokine secretion and investigate the effects of ADSC secretome in modulating microglia activation and the possible implication of sphingosine-1-phosphate (S1P) in these effects...
July 15, 2016: Stem Cells and Development
Pietro Randelli, Alessandra Menon, Vincenza Ragone, Pasquale Creo, Sonia Bergante, Filippo Randelli, Laura De Girolamo, Umberto Alfieri Montrasio, Giuseppe Banfi, Paolo Cabitza, Guido Tettamanti, Luigi Anastasia
Increasing the success rate of rotator cuff healing remains tremendous challenge. Among many approaches, the possibility of activating resident stem cells in situ, without the need to isolate them from biopsies, could represent valuable therapeutic strategy. Along this line, it has been recently demonstrated that lipoaspirate product, Lipogems, contains and produces growth-factors that may activate resident stem cells. In this study, human tendon stem cells (hTSCs) from the rotator cuff were cocultured in a transwell system with the Lipogems lipoaspirate product and compared to control untreated cells in terms of cell proliferation, morphology, stem cell marker and VEGF expression, and differentiation and migration capabilities...
2016: Stem Cells International
A M Saibene, C Pipolo, R Lorusso, S M Portaleone, G Felisati
OBJECTIVE: We evaluated a novel treatment for glottic insufficiency involving the injection of autologous material with direct glottic visualisation in an outpatient setting. METHODS: Three patients with vocal cord palsy underwent laryngoplasty under local anaesthesia using only a flexible endoscope with a working canal for Microfractured Fat Fibre-endoscopic Injection (MFFI). Adipose tissue was processed using the Lipogems device, which allows optimal purity, fluidity, and mesenchymal stem cell content in the resultant emulsion...
2015: B-ENT
Giovanni Cestaro, Michele De Rosa, Salvatore Massa, Bruno Amato, Maurizio Gentile
Faecal incontinence is a very debilitating problem. Many techniques have been proposed to treat this condition, with controversial results. Autologous transplant of fat tissue is an established procedure used for the repair of tissue damage, and recent studies revealed the potentiality of tissue regeneration by human adipose-derived stem cells. We treated this condition with the injection, in the intersphincteric anal groove, of lipoaspirate processed by an innovative technology (Lipogems). The aim of the study was to evaluate the efficacy of Lipogems injection for the treatment of faecal incontinence...
July 2015: Wideochirurgia i Inne Techniki Mało Inwazyjne, Videosurgery and Other Miniinvasive Techniques
Margherita Maioli, Salvatore Rinaldi, Sara Santaniello, Alessandro Castagna, Gianfranco Pigliaru, Alessandro Delitala, Francesca Bianchi, Carlo Tremolada, Vania Fontani, Carlo Ventura
Human adipose-derived stem cells (hASCs) have been recently proposed as a suitable tool for regenerative therapies for their simple isolation procedure and high proliferative capability in culture. Although hASCs can be committed into different lineages in vitro, the differentiation is a low-yield and often incomplete process. We have recently developed a novel nonenzymatic method and device, named Lipogems, to obtain a fat tissue derivative highly enriched in pericytes/mesenchymal stem cells by mild mechanical forces from human lipoaspirates...
2014: Cell Transplantation
Francesca Bianchi, Margherita Maioli, Erika Leonardi, Elena Olivi, Gianandrea Pasquinelli, Sabrina Valente, Armando J Mendez, Camillo Ricordi, Mirco Raffaini, Carlo Tremolada, Carlo Ventura
Adipose tissue contains multipotent elements with phenotypic and gene expression profiles similar to human mesenchymal stem cells (hMSCs) and pericytes. The chance of clinical translation of the multilineage potential of these cells is delayed by the poor/negligible cell survival within cryopreserved lipoaspirates, the difficulty of ex vivo expansion, and the complexity of current Good Manufacturing Practice (cGMP) requirements for expanded cells. Hence, availability of a minimally manipulated, autologous, hMSC/pericyte-enriched fat product would have remarkable biomedical and clinical relevance...
2013: Cell Transplantation
N Mylonakis, A Athanasiou, N Ziras, J Angel, A Rapti, S Lampaki, N Politis, C Karanikas, C Kosmas
BACKGROUND: Lipoplatin is a new liposomal cisplatin designed to reduce cisplatin toxicities without reducing efficacy. In the present randomized phase II study, we examined the efficacy and safety of a Lipoplatin-gemcitabine versus a cisplatin-gemcitabine combination as first line treatment in advanced NSCLC. PATIENTS AND METHODS: Patients with advanced (stages IIIB-IV) NSCLC received up to six 21-day cycles of Lipoplatin 120 mg/m(2) (days 1, 8, 15) and gemcitabine 1000 mg/m(2) (days 1+8) (arm A; LipoGem) versus cisplatin 100mg/m(2) (day 1) and gemcitabine 1000 mg/m(2) (days 1+8) (arm B; CisGem)...
May 2010: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"